Abstract:

Objective To study the effect of trilaciclib combined with chemotherapy on extensive small cell lung cancer (ES-SCLC). Methods A case of ES-SCLC patient treated with trilaciclib combined with chemotherapy in the First Affiliated Hospital of Xi'an Jiaotong University was retrospectively reviewed, and the related literatures were reviewed. Results The 56-year-old female patient was diagnosed with ES-SCLC of the left lung, large airway stenosis, and type I respiratory failure. She developed severe myelosuppression after receiving rescue chemotherapy, and gradually recovered after 11 days of drug administration and blood transfusion. After 5 cycles of chemotherapy combined with trilaciclib, severe myelosuppression was not reported, and chemotherapies were successfully completed. Conclusion The administration of trilaciclib within 4 h before chemotherapy in ES-SCLC patients can effectively reduce the degree of bone marrow suppression, shorten the duration of bone marrow suppression, and increase the tolerance to chemotherapy drugs without adverse impacts on the efficacy, suggesting clinical promotion.

Key words: small cell lung carcinoma, trilaciclib, chemotherapy, myelosuppression